Hookipa Pharma Inc. (HOOK) announced on Wednesday that it has received FDA clearance for its Investigational New Drug or IND application for HB-700, a new therapy for KRAS-mutated cancers.
The company also disclosed that with this IND submission, it will receive a final $10 million payment from Roche Holding AG (RHHBY).
As of April 25, 2024, the company will have full control over the associated intellectual property portfolio and complete collaboration and licensing rights for the HB-700 program.
The company plans to present preclinical data in an abstract at the American Society for Clinical Oncology 2024 Annual Meeting.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.